Trial Profile
An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Timrepigine emparvovec (Primary)
- Indications Choroideraemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms GEMINI
- Sponsors Biogen; Nightstar Therapeutics; NightstaRx
- 25 Jul 2022 Status changed from active, no longer recruiting to completed.
- 24 Jun 2022 Planned End Date changed from 2 Jun 2022 to 29 Jun 2022.
- 24 Jun 2022 Planned primary completion date changed from 2 Jun 2022 to 29 Jun 2022.